AstraZeneca’s shares jumped after Pfizer’s announcement of a major deal with the Trump administration.
Pfizer’s good news could benefit AstraZeneca, too.
Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early breast cancer. However, the main reason for AstraZeneca’s big gain was Pfizer‘s (NYSE: PFE) announcement of a deal with the Trump administration.
Pfizer CEO Albert Bourla appeared with President Donald Trump at a press conference on Tuesday to announce the landmark agreement. Pfizer plans to slash the prices on many of its prescription drugs in the U.S. and invest $70 billion in expanding its domestic operations. It will also participate in a new TrumpRx website that will help consumers find medications at discounted prices.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
In return, Pfizer will enjoy a three-year grace period during which it won’t be affected by the Trump administration’s tariffs on pharmaceutical imports to the U.S.
Good news for Pfizer could be good news for AstraZeneca, for two reasons.
First, President Trump hinted in the press conference earlier this week that other deals similar to Pfizer’s could be on the way. As the fourth-largest pharmaceutical company based on market cap, AstraZeneca is likely to be among the drugmakers lining up to follow in Pfizer’s footsteps.
Second, like Pfizer, AstraZeneca already has plans to expand in the U.S. CEO Pascal Soriot said in the company’s 2025 first-half update, “As we enter our next phase of growth, we have pledged $50 billion to continue to grow in the U.S., which includes the largest manufacturing investment in AstraZeneca’s history, set for Virginia.”
The bottom line is that the chances seem to be pretty good that his company will be able to secure an exemption from tariffs over the next three years, as Pfizer has.
Image source: Getty Images.
Some of the uncertainty that was hovering over the entire biopharmaceutical industry, including AstraZeneca, has now been lifted. Is the stock a buy? Maybe so.
For one thing, it is priced reasonably with a forward price-to-earnings ratio of around 15, and it continues to deliver strong earnings growth. The company is also making great strides with its pipeline, announcing more than a dozen positive results from late-stage clinical studies in recent months.
I think AstraZeneca should be able to deliver solid gains for long-term investors. It’s not the best pharma stock on the market, in my view, but it’s still a pretty good one.
Before you buy stock in AstraZeneca Plc, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AstraZeneca Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $631,456!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,147,755!*
Now, it’s worth noting Stock Advisor’s total average return is 1,064% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of September 29, 2025
Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
